Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
$6.16
-0.2%
$6.44
$4.74
$9.59
$2.35B1.341.31 million shs864,655 shs
Omnicell, Inc. stock logo
OMCL
Omnicell
$27.13
-1.1%
$27.68
$25.69
$77.14
$1.25B0.76540,423 shs500,170 shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$25.50
-1.5%
$28.76
$25.33
$48.60
$1.19B0.76492,049 shs305,832 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$35.33
-0.7%
$32.20
$15.44
$38.73
$5.82B1.541.38 million shs1.19 million shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
-0.16%+7.88%+3.53%-4.20%-21.23%
Omnicell, Inc. stock logo
OMCL
Omnicell
-1.09%-0.44%-2.72%-22.46%-54.11%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
-1.54%-2.30%-10.56%-20.44%-42.14%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-0.73%-1.40%+17.77%+27.32%+55.71%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
1.8688 of 5 stars
3.12.00.00.02.32.50.6
Omnicell, Inc. stock logo
OMCL
Omnicell
1.9902 of 5 stars
3.21.00.00.01.71.71.9
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
4.958 of 5 stars
4.53.00.03.92.32.53.1
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
4.022 of 5 stars
3.61.00.04.73.62.50.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
2.17
Hold$8.8343.40% Upside
Omnicell, Inc. stock logo
OMCL
Omnicell
2.33
Hold$42.2055.55% Upside
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
3.00
Buy$49.5094.12% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
3.10
Buy$41.2016.61% Upside

Current Analyst Ratings

Latest OMCL, LFST, PCRX, and RVMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2024
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$10.00 ➝ $10.00
4/12/2024
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$43.00 ➝ $45.00
4/10/2024
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Strong-Buy$36.00 ➝ $48.00
4/9/2024
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$45.00
4/8/2024
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $46.00
3/11/2024
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$43.00
3/7/2024
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$80.00 ➝ $45.00
3/6/2024
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$8.00 ➝ $9.00
3/4/2024
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$8.00 ➝ $9.00
3/4/2024
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$57.00
3/1/2024
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$53.00 ➝ $45.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
$1.06B2.22N/AN/A$3.77 per share1.63
Omnicell, Inc. stock logo
OMCL
Omnicell
$1.15B1.09$3.00 per share9.04$26.15 per share1.04
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$674.98M1.76$3.77 per share6.77$18.74 per share1.36
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M502.46N/AN/A$11.09 per share3.19

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
-$186.26M-$0.51N/AN/AN/A-17.64%-12.66%-8.65%5/9/2024 (Confirmed)
Omnicell, Inc. stock logo
OMCL
Omnicell
-$20.37M-$0.45N/A75.36N/A-1.78%3.43%1.81%5/2/2024 (Confirmed)
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$41.96M$0.8131.489.01N/A6.22%12.81%6.80%5/1/2024 (Estimated)
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$436.37M-$3.77N/AN/AN/AN/A-38.39%-33.61%5/13/2024 (Estimated)

Latest OMCL, LFST, PCRX, and RVMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
-$0.09N/A+$0.09N/AN/AN/A  
5/2/2024N/A
Omnicell, Inc. stock logo
OMCL
Omnicell
-$0.0830N/A+$0.0830N/AN/AN/A  
2/29/2024Q4 2023
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$0.71$0.71N/A$0.92$180.60 million$181.24 million
2/28/2024Q4 2023
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
-$0.09-$0.12-$0.03-$0.12$263.14 million$280.60 million
2/26/2024Q4 2023
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$0.85-$1.14-$0.29-$1.14$1.20 million$0.74 million    
2/8/2024Q4 2023
Omnicell, Inc. stock logo
OMCL
Omnicell
-$0.10$0.12+$0.22$0.56$256.00 million$258.85 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
N/AN/AN/AN/AN/A
Omnicell, Inc. stock logo
OMCL
Omnicell
N/AN/AN/AN/AN/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
0.20
1.11
1.11
Omnicell, Inc. stock logo
OMCL
Omnicell
0.48
2.52
2.22
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.59
5.24
4.17
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/A
13.06
13.06

Ownership

Institutional Ownership

CompanyInstitutional Ownership
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
85.50%
Omnicell, Inc. stock logo
OMCL
Omnicell
97.70%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
99.73%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%

Insider Ownership

CompanyInsider Ownership
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
8.50%
Omnicell, Inc. stock logo
OMCL
Omnicell
2.64%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
6.60%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
8.50%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
9,325380.69 million348.33 millionOptionable
Omnicell, Inc. stock logo
OMCL
Omnicell
3,65045.92 million44.71 millionOptionable
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
71246.52 million43.43 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
378164.69 million150.69 millionOptionable

OMCL, LFST, PCRX, and RVMD Headlines

SourceHeadline
SG Americas Securities LLC Trims Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)SG Americas Securities LLC Trims Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)
marketbeat.com - April 20 at 4:12 AM
Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Bought by Mirae Asset Global Investments Co. Ltd.Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Bought by Mirae Asset Global Investments Co. Ltd.
marketbeat.com - April 19 at 4:39 AM
Validea Detailed Fundamental Analysis - RVMDValidea Detailed Fundamental Analysis - RVMD
nasdaq.com - April 17 at 2:28 PM
Revolution Medicines (RVMD) Price Target Increased by 5.15% to 41.65Revolution Medicines (RVMD) Price Target Increased by 5.15% to 41.65
msn.com - April 17 at 2:28 PM
Revolution Medicines executive sells over $619k in company stockRevolution Medicines executive sells over $619k in company stock
investing.com - April 15 at 12:41 AM
Revolution Medicines director sells shares worth $79,735Revolution Medicines director sells shares worth $79,735
investing.com - April 14 at 9:40 AM
Insider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) Director Sells 2,155 Shares of StockInsider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) Director Sells 2,155 Shares of Stock
insidertrades.com - April 13 at 7:10 AM
Insider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) Insider Sells 7,500 Shares of StockInsider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) Insider Sells 7,500 Shares of Stock
marketbeat.com - April 12 at 9:27 PM
Revolution Medicines, Inc. (NASDAQ:RVMD) Short Interest Down 26.8% in MarchRevolution Medicines, Inc. (NASDAQ:RVMD) Short Interest Down 26.8% in March
marketbeat.com - April 12 at 2:50 PM
Buy Rating Justified by Revolution Medicines’ Promising Preclinical Data in KRAS Mutant Cancer TherapiesBuy Rating Justified by Revolution Medicines’ Promising Preclinical Data in KRAS Mutant Cancer Therapies
markets.businessinsider.com - April 12 at 2:35 PM
Revolution Medicines (NASDAQ:RVMD) PT Raised to $45.00 at OppenheimerRevolution Medicines (NASDAQ:RVMD) PT Raised to $45.00 at Oppenheimer
marketbeat.com - April 12 at 8:27 AM
Revolution Medicines reports progress in RAS cancer therapyRevolution Medicines reports progress in RAS cancer therapy
uk.investing.com - April 11 at 7:19 PM
Revolution Medicines (NASDAQ:RVMD) Reaches New 52-Week High at $37.62Revolution Medicines (NASDAQ:RVMD) Reaches New 52-Week High at $37.62
marketbeat.com - April 11 at 3:20 PM
Whats Going On With Revolution Medicines Stock?What's Going On With Revolution Medicines Stock?
msn.com - April 10 at 2:34 PM
Revolution Medicines (NASDAQ:RVMD) Upgraded to "Strong-Buy" at Raymond JamesRevolution Medicines (NASDAQ:RVMD) Upgraded to "Strong-Buy" at Raymond James
marketbeat.com - April 10 at 9:08 AM
Revolution Medicines reports breakthrough in RAS-mutant cancer treatmentRevolution Medicines reports breakthrough in RAS-mutant cancer treatment
uk.investing.com - April 10 at 1:37 AM
Revolutionary therapeutic shows promise for pancreatic cancer treatmentRevolutionary therapeutic shows promise for pancreatic cancer treatment
news-medical.net - April 9 at 3:36 PM
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) ProteinsRevolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
globenewswire.com - April 9 at 3:34 PM
Revolution Medicines’ Robust Cancer Drug Pipeline Justifies Buy RatingRevolution Medicines’ Robust Cancer Drug Pipeline Justifies Buy Rating
markets.businessinsider.com - April 8 at 2:23 PM
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) ProteinsRevolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
globenewswire.com - April 8 at 11:36 AM
Needham & Company LLC Reiterates "Buy" Rating for Revolution Medicines (NASDAQ:RVMD)Needham & Company LLC Reiterates "Buy" Rating for Revolution Medicines (NASDAQ:RVMD)
marketbeat.com - April 8 at 8:20 AM
Revolution Medicines to Participate in Upcoming Investor ConferencesRevolution Medicines to Participate in Upcoming Investor Conferences
globenewswire.com - April 4 at 4:05 PM
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Consensus Rating of "Buy" from BrokeragesRevolution Medicines, Inc. (NASDAQ:RVMD) Receives Consensus Rating of "Buy" from Brokerages
marketbeat.com - April 2 at 4:22 AM
Insider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Sells 1,500 Shares of StockInsider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Sells 1,500 Shares of Stock
insidertrades.com - March 29 at 8:56 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

LifeStance Health Group logo

LifeStance Health Group

NASDAQ:LFST
LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.
Omnicell logo

Omnicell

NASDAQ:OMCL
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Pacira BioSciences logo

Pacira BioSciences

NASDAQ:PCRX
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Revolution Medicines logo

Revolution Medicines

NASDAQ:RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.